BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

NCT01519323 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

6

Enrollment

INDUSTRY

Sponsor class

Stopped Study was terminated due to low enrollment.

Conditions

Malignant Melanoma

Interventions

DRUG: vemurafenib

Sponsor

Hoffmann-La Roche